AR081908A1 - N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas - Google Patents
N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismasInfo
- Publication number
- AR081908A1 AR081908A1 ARP110101610A ARP110101610A AR081908A1 AR 081908 A1 AR081908 A1 AR 081908A1 AR P110101610 A ARP110101610 A AR P110101610A AR P110101610 A ARP110101610 A AR P110101610A AR 081908 A1 AR081908 A1 AR 081908A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- preparation
- espirolactama
- bipirrolidinas
- heteroaril
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Más específicamente, los compuestos son moduladores de los receptores H3 y, por lo tanto, son útiles como agentes farmacéuticos, especialmente en el tratamiento y/o prevención de una variedad de enfermedades moduladas por los receptores H3, incluyendo enfermedades asociadas con el sistema nervioso central. Además, también describe métodos de preparación de N-heteroaril-espirolactama-bipirrolidinas de fórmula (1) y compuestos intermedios para los mismos.Reivindicación 1: Un compuesto de fórmula (1) en la que m, p = 1 ó 2; n, s = 1 ó 2; X es O, NR3 o CR4R5; Q1 a Q4 son independientemente CH o N, con la condición de que al menos uno de Q1 a Q4 sea N; R1 es hidrógeno, alquilo C1-4, CF3 o alcoxi C1-4; R2 es hidrógeno, halógeno, alquilo C1-4, alcoxi C1-4 o CF3; R3 es hidrógeno o alquiloxi C1-6-carbonilo; R4 es hidrógeno; y R5 es hidrógeno u OH; o una sal del mismo o un enantiómero o un diastereoisómero del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33339310P | 2010-05-11 | 2010-05-11 | |
| FR1061074 | 2010-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081908A1 true AR081908A1 (es) | 2012-10-31 |
Family
ID=44305055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101610A AR081908A1 (es) | 2010-05-11 | 2011-05-10 | N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8796278B2 (es) |
| EP (1) | EP2569304A1 (es) |
| JP (1) | JP5833105B2 (es) |
| AR (1) | AR081908A1 (es) |
| TW (1) | TW201202251A (es) |
| WO (1) | WO2011143148A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011143148A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| CN116478131A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| EP4230623A3 (en) | 2017-01-23 | 2023-10-11 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| EP3694848A1 (en) * | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| KR102716960B1 (ko) * | 2017-11-03 | 2024-10-11 | 브리스톨-마이어스 스큅 컴퍼니 | 디아자스피로 rock 억제제 |
| AU2018385713A1 (en) | 2017-12-15 | 2020-06-18 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
| KR102581268B1 (ko) | 2019-09-03 | 2023-09-22 | 주식회사 엘지화학 | 에어로겔 블랭킷 제조방법 |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3960961A (en) | 1970-08-31 | 1976-06-01 | The Upjohn Company | 4'-Fluoro-4-{[4-(phenyl)cyclohexyl]amino}butyrophenones and the salts thereof |
| US20030073836A1 (en) | 2001-07-05 | 2003-04-17 | Boehringer Ingelheim Pharma Kg | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions |
| WO2004037257A1 (en) * | 2002-10-23 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1669350B1 (en) | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
| GB0405628D0 (en) | 2004-03-12 | 2004-04-21 | Glaxo Group Ltd | Novel compounds |
| PT1755593E (pt) | 2004-06-02 | 2008-03-17 | Hoffmann La Roche | Derivados de naftaleno úteis como ligandos de receptores histamina-3 |
| US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| ES2367515T3 (es) * | 2004-10-19 | 2011-11-04 | F. Hoffmann-La Roche Ag | Derivados de quinolina. |
| JP5085330B2 (ja) | 2004-10-21 | 2012-11-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なトリアゾール |
| EP1866293A1 (en) * | 2005-03-31 | 2007-12-19 | UCB Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| ATE530519T1 (de) | 2005-06-03 | 2011-11-15 | Abbott Lab | Cyclobutylaminderivate |
| EP1790646A1 (fr) * | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
| JP5175228B2 (ja) * | 2006-02-15 | 2013-04-03 | サノフイ | 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用 |
| US20080247964A1 (en) * | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| TW200918062A (en) | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| WO2009039431A2 (en) | 2007-09-21 | 2009-03-26 | Neurogen Corporation | Substituted aryl-fused spirocyclic amines |
| BRPI0818626A2 (pt) * | 2007-10-17 | 2015-09-29 | Sanofi Aventis | n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma |
| WO2009052062A1 (en) | 2007-10-17 | 2009-04-23 | Sanofi-Aventis | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |
| CA2702834C (en) | 2007-10-17 | 2013-01-15 | Sanofi-Aventis | Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof |
| AU2008312641A1 (en) | 2007-10-17 | 2009-04-23 | Sanofi-Aventis | Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof |
| MX2011000460A (es) | 2008-07-18 | 2011-03-15 | Takeda Pharmaceutical | Derivados de benzazepina y su uso como antagonistas de histamina h3. |
| WO2010047956A1 (en) * | 2008-10-08 | 2010-04-29 | Bristol-Myers Squibb Company | Azolopyrrolone melanin concentrating hormone receptor-1 antagonists |
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
| AR074467A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
| WO2011143148A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
-
2011
- 2011-05-10 WO PCT/US2011/035824 patent/WO2011143148A1/en not_active Ceased
- 2011-05-10 JP JP2013510220A patent/JP5833105B2/ja not_active Expired - Fee Related
- 2011-05-10 TW TW100116248A patent/TW201202251A/zh unknown
- 2011-05-10 AR ARP110101610A patent/AR081908A1/es unknown
- 2011-05-10 EP EP11731172A patent/EP2569304A1/en not_active Withdrawn
-
2012
- 2012-11-06 US US13/670,067 patent/US8796278B2/en not_active Expired - Fee Related
-
2014
- 2014-06-27 US US14/318,272 patent/US9533995B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20130059863A1 (en) | 2013-03-07 |
| US20140315923A1 (en) | 2014-10-23 |
| EP2569304A1 (en) | 2013-03-20 |
| JP2013526526A (ja) | 2013-06-24 |
| US9533995B2 (en) | 2017-01-03 |
| JP5833105B2 (ja) | 2015-12-16 |
| WO2011143148A1 (en) | 2011-11-17 |
| US8796278B2 (en) | 2014-08-05 |
| TW201202251A (en) | 2012-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081908A1 (es) | N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas | |
| EA202190619A1 (ru) | Противовирусные соединения | |
| EA201490747A1 (ru) | 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний | |
| UY35012A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| CR10948A (es) | Compuestos triciclicos, composiciones y procedimientos | |
| AR099994A1 (es) | Compuesto de ciclopropanamina y sus usos | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| CR20190244A (es) | Agentes control de plaga | |
| EA201301320A1 (ru) | 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу | |
| EA201400569A1 (ru) | Новые производные циклогексиламина, обладающие агонистической активностью по отношению к бета-2 адренергическому рецептору и антагонистической активностью по отношению к мускариновому рецептору м3 | |
| EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
| PE20181357A1 (es) | Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| CY1112083T1 (el) | Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση | |
| EA201270778A1 (ru) | Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119 | |
| EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
| UY33484A (es) | Derivados de dioxido de 1,3-propano sustituidos por espirociclos, procedimientos de obtencion y uso medico | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| UY31803A (es) | Compuesto cristalino | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| BR112013028598A2 (pt) | método para promover o crescimento de plantas | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |